All Articles

Value-based drug purchasing, better coordination of care delivery, and earlier institution of palliative care were among the measures to lower the cost of cancer care that were suggested during a panel discussion at the 2020 virtual National Comprehensive Cancer Network (NCCN) Oncology Policy Summit. The discussion was moderated by Clifford Goodman, PhD, Senior Vice President, Comparative Effectiveness Research, the Lewin Group. Read More ›

On August 17, 2020, the Centers for Medicare & Medicaid Services (CMS) published its proposed plans for payment and reporting changes for 2021. In contrast to previous years on record, the final rule is likely to be released in early December instead of early November. This means that there may be less than 30 days to prepare and implement changes prior to January 1, 2021. Read More ›

The urgent international push to develop a vaccine for the novel coronavirus represents an unprecedented effort, said experts at the Association for Value-Based Cancer Care’s final summer webinar on COVID-19 and cancer care, which was held August 27. Read More ›

When it comes to your company, there is no greater asset than a healthy team culture. As it has been said many times, “Team culture eats company strategy for breakfast.” You can have the best strategy, the strongest marketing, and the greatest profitability. However, if you do not also have a healthy team culture, your long-term success is doomed to failure. Read More ›

Patients with cancer and cancer treatment dynamics continue to bounce back toward baseline as of late summer 2020, reported experts at the Association for Value-Based Cancer Care August 20 webcast, which focused on economic trends in cancer care during the COVID-19 pandemic. Read More ›

Genetic testing can play an important role in determining a patient’s risk for developing certain cancers and can be used to individualize treatment for better clinical outcomes. In a recent study published online in JAMA Oncology, researchers reported that universal multigene panel testing among patients with solid tumors was associated with increased detection of mutations compared with targeted testing based on standard guidelines. Read More ›

Until the late 1930s, stomach cancer—also called gastric cancer—was the leading cause of cancer death in the United States. Although stomach cancer is still a major cause of cancer-related deaths worldwide, it is now much less common in this country. Read More ›

Rucaparib (Rubraca, Clovis Oncology) demonstrated promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA alteration, according to results of a study published online in the Journal of Clinical Oncology. Read More ›

Black men with low-risk prostate cancer who were on active surveillance had an increased risk for disease progression and definitive treatment compared with their non-Hispanic White counterparts, but not increased mortality, according to the results of a recent study. Read More ›